These clinical data support the potential of gastrin as a therapeutic in combination with other diabetes therapies. Transition holds the exclusive rights to a series of proprietary gastrin based combination therapies including GLP1-I.N.T.(TM) (a combination of gastrin analogue, G1, and a GLP-1 analogue) and combination therapies of gastrins and DPP-IV inhibitors. Transition will continue the development of these combination therapies into clinical trials with type 1 and type 2 diabetes patients.
Transition's second Islet Neogenesis Therapy product, GLP1-I.N.T.(TM) is a combination of one of the leading diabetes drug candidates, Glucagon-Like-Peptide-1 ("GLP-1"), with G1. The Company will perform additional safety and tolerability studies in humans in preparation for Phase II clinical development. The Company has entered into an agreement with the JDRF to support the clinical development of GLP1-I.N.T.(TM) over the next two years.
Sustaining Financial Strength
During the year ended June 30, 2007, the Company strengthened its cash
position by completing an offering for 2,986,867 common shares for net cash
proceeds of $23,964,751. Subsequent to the end of the year, the Company
further strengthened its cash position by completing another private
placement, issuing 1,736,107 common shares resulting in net cash proceeds
of $23,976,404. The Company's cash and cash equivalents and short-term
investments were $34,368,142 at June 30, 2007. The Company currently
|SOURCE Transition Therapeutics Inc.|
Copyright©2007 PR Newswire.
All rights reserved